Nektar bags $70M milestone as AstraZeneca takes constipation drug to FDA

The FDA has accepted an NDA for Nektar Therapeutics' ($NKTR) naloxegol, triggering a $70 million milestone payment from partner AstraZeneca ($AZN). The drug, designed to treat painkiller-induced constipation in patients with chronic pain, works by blocking mu-opioid receptors, and Nektar licensed the therapy to AstraZeneca back in 2009. More

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.